文献速递炎症性肠病

克罗恩病抗TNF治疗与肠切除风险:一项基于人群的队列研究

Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2017-07-28

该研究基于瑞典国家患者登记库2006–2014年数据,纳入1856例首次接受阿达木单抗或英夫利西单抗的未手术克罗恩病患者,随访至7年。TNFi暴露后第1–7年累积肠切除率分别为7%、13%、17%、20%、23%、25%和28%;持续治疗≥12个月与<12个月者肠切除率相似(P=.27),未识别出预测因素。

要点

  • TNFi治疗后第1–7年累积肠切除率依次为7%、13%、17%、20%、23%、25%、28%。
  • TNFi持续≥12个月与<12个月者肠切除率相似(P=.27)。
  • 未识别出性别、年龄、病变范围或病程等肠切除预测因素。

核心结论

  • 开始抗TNF治疗后肠切除风险在常规医疗中高于已发表的随机对照试验。
  • 持续TNFi治疗超过12个月的患者与更早停药者肠切除率相似。

研究设计与样本

  • 基于登记资料的观察性队列研究,地点为瑞典,时间为2006–2014年。
  • 通过瑞典国家患者登记库1987–2014年识别克罗恩病患者,评估2006年起首次配发阿达木单抗或英夫利西单抗后肠切除发生率,随访至7年。
  • 共纳入1856例曾接受TNFi的克罗恩病患者。

主要发现

  • TNFi开始后6个月治疗留存率为90%,12个月后仍有65%继续用药。
  • TNFi暴露的克罗恩病患者第1–7年累积手术率分别为7%、13%、17%、20%、23%、25%和28%。
  • TNFi生存期<12个月与≥12个月的患者肠切除率相似(P=.27)。
  • 未识别出肠切除的预测因素(如性别、年龄、病变范围或病程)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TNF inhibitors (TNFi) have been shown to reduce the need for surgery in Crohn's disease, but few studies have examined their effect beyond the first year of treatment. AIM: To conduct a register-based observational cohort study in Sweden 2006-2014 to investigate the risk of bowel resection in bowel surgery naïve TNFi-treated Crohn's disease patients and whether patients on TNFi ≥12 months are less likely to undergo bowel resection than patients discontinuing treatment before 12 months. METHODS: We identified all individuals in Sweden with Crohn's disease through the Swedish National Patient Register 1987-2014 and evaluated the incidence of bowel resection after first ever dispensation of adalimumab or infliximab from 2006 and up to 7 years follow-up. RESULTS: We identified 1856 Crohn's disease patients who had received TNFi. Among these patients, 90% treatment retention was observed at 6 months after start of TNFi and 65% remained on the drug after 12 months. The cumulative rates of surgery in Crohn's disease patients exposed to TNFi years 1-7 were 7%, 13%, 17%, 20%, 23%, 25% and 28%. Rates of bowel resection were similar between patients with TNFi survival <12 months and ≥12 months respectively (P=.27). No predictors (eg, sex, age, extension or duration of disease) for bowel resection were identified. CONCLUSIONS: The risk of bowel resection after start of anti-TNF treatment is higher in regular health care than in published RCTs. Patients on sustained TNFi treatment beyond 12 months have bowel resection rates similar to those who discontinue TNFi treatment earlier.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Eberhardson M, Söderling JK, Neovius M, et al. Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther. 2017. PMID: 28752637. doi:10.1111/apt.14224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。